New role for an established drug? Bisphosphonates as potential anticancer agents (Q37923744)

25 August 2017

1 reference

title

New role for an established drug? Bisphosphonates as potential anticancer agents (English)

1 reference

25 August 2017

H K Koul

1

1 reference

25 August 2017

S Koul

series ordinal

2

1 reference

25 August 2017

R B Meacham

series ordinal

3

1 reference

25 August 2017

publication date

30 August 2011

1 reference

Prostate Cancer and Prostatic Diseases

25 August 2017

published in

1 reference

25 August 2017

volume

15

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

111-119

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2011.41

25 August 2017

exact match

0 references

cites work

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Preclinical pharmacology of the taxanes: implications of the differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

The distribution of secondary growths in cancer of the breast. 1889

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Targeting the mevalonate pathway for improved anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Activation of γδ T cells by bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Zoledronate Stimulates γδ T Cells in Prostate Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Is cancer a disease of self-seeding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Bisphosphonates for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Bisphosphonates: preclinical review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.41

31 March 2020

Identifiers

DOI

10.1038/PCAN.2011.41

1 reference

Dimensions Publication ID

25 August 2017

1003914037

0 references

Fatcat ID

release_uxcazthvtnefpbkxq54gqqyzqi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uxcazthvtnefpbkxq54gqqyzqi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference